CAS: 128779-47-5; (R)-3-([1,1'-Biphenyl]-4-yl)-2-((Tert-Butoxycarbonyl)Amino)Propanoic Acid

该化合物是受保护的氨酸,通常用于化合成."乙酸"(乙基-丁基氧碳基)组是氨基功能的保护组,允许有选择的反应,而不会干扰该矿.苯丙烯的侧链上有4个苯基组,有助于分子的疏水特性,影响其溶解性和生物系统中的相互作用.该化合物一般是白色到白色的,在二氯甲烷和二甲基硫氧化物等有机溶剂中溶解,但水中溶液较少.其结构允许引入气性,使其在生物活性和药物的合成中具有价值.该混合物在标准实验室条件下的稳定使其成为有机合成的有用中间体.此外,在酸性条件下,可以对有机-4-苯-D-Phe-OHH进行保护,以产生自由的氨基酸,然后可以参与进一步的化学反应或生物应用.

英文名称(R)-3-([1,1'-Biphenyl]-4-yl)-2-((Tert-Butoxycarbonyl)Amino)Propanoic Acid
中文名称(R)-3-([1,1'-联苯]-4-基)-2-((叔丁氧基羰基)氨基)丙酸
IUPAC名称(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-phenylphenyl)propanoic acid
其它别名B°C-D-PHE(4-PHENYL)-OH; B°C-D-BPH-OH; B°C-D-BIP(4,4')-OH; B°C-D-BIP-OH; B°C-D-ALA(4,4'-BIPHENYL)-OH; B°C-3-(4-BIPHENYLYL)-D-ALANINE; B°C-4-PHENYL-D-PHENYLALANINE; B°C-4-PHENYL-D-PHE-OH
CAS编号128779-47-5
MFCD编号:MFCD00191185
EINECS号:852-973-3
FDA UNII编号:8SFR66TT6A
分子式:C20H23NO4
分子量:341.4
产品CID: 448934
产品分类有机原料→生命科学→氨基酸及其衍生物→丙氨酸及其衍生物

相似结构搜索
InChIKey: NBVVKAUSAGHTSU-QGZVFWFLSA-N
1S/C20H23NO4/c1-20(2,3)25-19(24)21-17(18(22)23)13-14-9-11-16(12-10-14)15-7-5-4-6-8-15/h4-12,17H,13H2,1-3H3,(H,21,24)(H,22,23)/t17-/m1/s1…
计算化学: 氢键受体数3.0氢键供体数2.0可旋转键数5.0

相似化合物

147923-08-8 199110-64-0 205526-38-1

MSDS等安全信息

GHS符号GHS07
警示词Warning
危险描述H302-H315-H319-H335
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
危险品标志Xi
安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body

上下游产品

CAS号149709-62-6 沙库比曲

合成工艺路线路线简述

Methyl N-(Tert-Butoxycarbonyl)-O-[(Trifluoromethyl)Sulfonyl]-D-Tyrosinate置于四(三苯基膦)钯 Sodium Hydroxide,Potassium Carbonate体系中,用四氢呋喃,甲醇,甲苯用作溶剂,化学反应 2.0H,反应生成N-叔丁氧羰基-3-(4-联苯基)-D-丙氨酸
参考文献:Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors
标题:Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors
摘要:The Synthesis Of Three Series Of Dicarboxylic Acid Dipeptide Neutral Endopeptidase 24.11 (Nep) Inhibitors Is Described. In Particular,The Amino Butyramide 21A Exhibited Potent Nep Inhibitory Activity (Ic50 = 5.0 Nm) In Vitro And In Vivo. Blood Levels Of 21A Were Determined Using An Ex Vivo Method By Measuring Plasma Inhibitory Activity In Conscious Rats,Mongrel Dogs,And Cynomolgus Monkeys. Free Drug Concentrations Were 10-1500 Times Greater Than The Inhibitory Constant For Nep Over The Course Of A 6 H Experiment. A Good Correlation Of Free Drug Concentrations Was Obtained When Comparing Values Determined By The Ex Vivo Analysis To Those Calculated From Direct HPLC Measurements. Plasma Atrial Natriuretic Factor (Exogenous) Levels Were Elevated In Rats And Dogs After Oral Administration Of 19A. Urinary Volume And Urinary Sodium Excretion Were Also Potentiated In Anesthetized Dogs Treated With 21A.
Doi:10.1021/jm00010A014

海关参考信息

2902600000-乙苯
2905122000-异丙醇
2905143000-叔丁醇
2912110000-甲醛
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-2016200665-A1
优先权日:2013-08-21
标题:Synthesis of biphenylalaninol via novel intermediates
发明人：ZIMMERMANN AXEL; HERMSEN PETRUS JOHANNES; HANBAUER MARTIN HELMUT FRIEDRICH
权利人:DPX HOLDINGS BV
摘要:The invention relates to a novel synthesis route towards R-biphenylalaninol and to the intermediates applied in this synthesis route. The process according to the invention and the intermediate compounds are useful in the synthesis of pharmaceutically active compounds.